Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
In order to determine the difference in reactivity of factor (F) VIII inhibitors against the FVIII/von Willebrand factor (vWF) complex and against vWF-deficient FVIII, we investigated a panel of 10 antibodies to FVIII from multitransfused individuals with severe haemophilia A and other pathologies. Immunoblotting of purified FVIII and purified thrombin-cleaved FVIII revealed that in all cases inhibitor epitopes could be localized in the heavy chain (A2 subunit) while in four cases they were also present in the light chain. One of the FVIII inhibitors remained unclassified. The effect on FVIII:C of purified IgG from inhibitor plasmas was tested against a high purity FVIII/vWF concentrate and a monoclonally purified FVIII concentrate with only trace contents of vWF, by two different functional assays. Our results suggest that for those inhibitors showing A2 plus light chain (LC) reactivity, the IgG concentration required to inhibit 50% of FVIII activity in vitro is higher for the FVIII/vWF complex than for the vWF-deficient FVIII. We conclude that there might be a protective role of vWF (at least in vitro) against FVIII inhibitors with A2 and LC subunit specificity.
Gensana
M
M
Research and Development Area, Instituto Grifols, SA, Barcelona, Spain. marta.gensana@grifols.com
Altisent
C
C
Aznar
J A
JA
Casaña
P
P
Hernández
F
F
Jorquera
J I
JI
Magallón
M
M
Massot
M
M
Puig
L
L
D000906:Antibodies / Q000097:blood / Q000276:immunology*; D000918:Antibody Specificity; D000937:Antigen-Antibody Reactions; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D006467:Hemophilia A / Q000097:blood / Q000188:drug therapy / Q000276:immunology*; D006801:Humans; D014841:von Willebrand Factor / Q000276:immunology*
D000906:Antibodies; D014841:von Willebrand Factor; D005169:Factor VIII